Journal of Renal Nutrition
Volume 21, Issue 3 , Pages 277-282 , May 2011

Lanthanum Carbonate Provides Control of Phosphorus Levels in Patients New to Phosphate Binder Therapy and Patients Changed From Other Phosphate Binders

Portions of this manuscript have been presented at the National Kidney Foundation Spring Clinical Meetings from March 25 through March 29, 2009, in Nashville, TN

  • Linda Noto, RD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Linda Noto, RD, Pentec Health, 4 Creek Parkway, Suite A, Boothwyn, PA 19061.

References 

  1. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  2. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520–528
  3. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–201
  4. Danese MD, Belozeroff V, Smirnakis K, et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1423–1429
  5. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006;65:191–202
  6. Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract. 2006;102:c61–c71
  7. Mehrotra R, Martin KJ, Fishbane S, et al. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008;3:1437–1445
  8. Tomasello S, Dhupar S, Sherman RA. Phosphate binders, K/DOQI guidelines, and compliance: the unfortunate reality. Dial Transplant. 2004;33:236–240
  9. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004;65:1914–1926
  10. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4:1089–1096
  11. Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. Am J Clin Nutr. 2008;88:1511–1518
  12. Pifer TB, McCullough KP, Port FK, et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int. 2002;62:2238–2245
  13. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999;156:5–10

 Linda Noto has served as member of a speakers' bureau for Shire Pharmaceuticals and has received editorial support funded by Shire Pharmaceuticals for this manuscript.

PII: S1051-2276(10)00110-X

doi: 10.1053/j.jrn.2010.04.007

Journal of Renal Nutrition
Volume 21, Issue 3 , Pages 277-282 , May 2011

Article Tools

* Image Usage & Resolution